11 April 2019 - - Israeli generic drug specialist Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a new USD 2.3bn unsecured revolving credit facility, which replaces its existing USD 3bn credit facility, the company said.

Bank of America, Merrill Lynch and HSBC Bank plc are Coordinating Bookrunners and Mandated Lead Arrangers for the facility.

The syndicate also includes Barclays Bank PLC, BNP Paribas, Citibank N.A., Credit Suisse AG, Goldman Sachs Bank USA, JPMorgan Chase Bank N.A., Mizuho Bank LTD., Morgan Stanley Bank N.A., Morgan Stanley Senior Funding, INC., MUFG Bank LTD., Sumitomo Mitsui Banking Corp. and PNC Bank National Association as Bookrunners and Mandated Lead Arrangers, and Banca IMI as lead arranger.

Teva Pharmaceutical is in generic medicines, but has innovative treatments in select areas, including CNS, pain and respiratory.

The company has an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R and D function, strong operational base and global infrastructure and scale.

Headquartered in Israel, with production and research facilities around the globe, Teva employs 45,000 professionals, committed to improving the lives of millions of patients.